ReviewMolecular diagnosis & therapy2020
Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.
Review in Molecular diagnosis & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of diagnostic cell-free circulating microRNAs for breast cancer detection.BMC cancer · 2022Pooled it
- Prognostic and Clinicopathological Significance of MiR-155 in Breast Cancer: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Cancer vaccines and RNA therapeutics: exploring the impact of microRNAs.NPJ vaccines · 2026Review
- MicroRNAs as Endocrine Modulators of Breast Cancer.International journal of molecular sciences · 2025Review
- Deguelin's Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry.Frontiers in pharmacology · 2025Review
- Confirmation of previously identified plasma microRNA ratios for breast cancer detection in a nested case-control study within a screening setting.Clinical and translational medicine · 2024Article
- Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.Frontiers in cell and developmental biology · 2024Review
- The role of miRNAs as biomarkers in breast cancer.Frontiers in oncology · 2024Review
- Plasma microRNA ratios associated with breast cancer detection in a nested case-control study from a mammography screening cohort.Scientific reports · 2023Article
- A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery.Medical oncology (Northwood, London, England) · 2022Review
- Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers.Molecular biology reports · 2022Article
- Commentary: Polygenic risk for breast cancer: in search for potential clinical utility.International journal of epidemiology · 2022Article
- Potential utility of miRNAs for liquid biopsy in breast cancer.Frontiers in oncology · 2022Review
- Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer.Journal of clinical laboratory analysis · 2021Article
- Ketogenic Diet in Cancer Prevention and Therapy: Molecular Targets and Therapeutic Opportunities.Current issues in molecular biology · 2021Review
- hsa-miR-33-5p as a Therapeutic Target Promotes Apoptosis of Breast Cancer CellsFrontiers in medicine · 2021Article
- Circulating miR-320a Acts as a Tumor Suppressor and Prognostic Factor in Non-small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Ready-to-use nanopore platform for the detection of any DNA/RNA oligo at attomole range using an Osmium tagged complementary probe.Scientific reports · 2020Article
- Three dimensional engineered models to study hypoxia biology in breast cancer.Cancer letters · 2020Review
- Connecting the Missing Dots: ncRNAs as Critical Regulators of Therapeutic Susceptibility in Breast Cancer.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the second most common cause of deaths reported in women worldwide, and therefore there is a need to identify breast cancer patients at an early stage as timely diagnosis would help in effective management and appropriate monitoring of patients. Nevertheless, it is challenging to achieve these goals due to the lack of a specific biomarker for early detection and monitoring in breast cancer. Recently, microRNAs (miRNAs) have emerged as master regulators of the molecular pathways highlighted in different tumors leading to progression in malignancies. With the rapid advancements in molecular research, the potential to use miRNAs as prognostic and diagnostic biomarkers in breast cancer has been highlighted, as their dysregulation is directly associated with breast cancer progression and metastasis. The ease of detection and long-term stability of circulating miRNAs in blood makes them a promising candidate for non-invasive breast cancer biomarkers.
Indexed as
Identifiers
32067191What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.